SPY380.36-1.97 -0.52%
DIA309.45-4.53 -1.44%
IXIC13,192.35+72.96 0.56%

Pfizer Gets Patent Term Extension for Breast Cancer Combination Treatment

· 02/05/2021 02:10

07:04 AM EST, 02/05/2021 (MT Newswires) -- Pfizer (PFE) said early on Friday that it has received a patent term extension in the US for Ibrance, an indication for the treatment of advanced or metastatic breast cancer as part of a combination therapy.

The certificate granted by the US Patent and Trademark Office extends the term by more than four years to March 5, 2027, according to a statement.

The company said Ibrance is currently approved in more than 100 countries and has been prescribed to more than 350,000 patients globally.

Price: 34.93, Change: +0.04, Percent Change: +0.11